Deliver with tumor lysis syndrome (TLS) prophylaxis, a 28-day venetoclax window in cycle 1, then 7–14 days in deep responders, cycle-by-count re-dosing, and azole-aware CYP3A adjustments. The gene discussed is CYP3A4; the disease is Tumor Lysis Syndrome.